Structure Therapeutics Research Costs Climb To $134.6 Million From $59 Million As Trial Spending Rises
The oral obesity drug developer expects its cash to last through 2028, excluding commercial preparation and manufacturing costs.
Structure Therapeutics, which develops experimental oral obesity medicines, spent $134.6 million on research in the third quarter, against $59 million a year earlier, according to its Monday SEC earnings filing. The company attributed the increase primarily to clinical trials, preclinical work and employee costs, while its funding forecast through 2028 excludes preparations for commercialization and commercial manufacturing.
Bigger Trials, A Wider Loss
Structure's quarterly net loss widened to $144.8 million, from $65.7 million a year earlier. Those losses included non-cash stock compensation of $12.7 million and $7.5 million, respectively.
Administrative expenses reached $21.8 million, compared with $14.8 million. Structure attributed that increase mainly to employee costs as it expanded the infrastructure supporting its operations. For the first nine months, its net loss totaled $326.9 million, versus $174.2 million a year earlier.
Cash, cash equivalents and short-term investments stood at $1.2 billion at September's end, down from $1.3 billion at June's end. Management expects that money to cover projected operations and key clinical milestones through the end of 2028, including aleniglipron's late-stage program—but not the additional costs of preparing to sell and commercially manufacture its medicines.
Aleniglipron's Long-Term Test
Structure designs small-molecule medicines using three-dimensional protein structures and computational chemistry. Its most advanced candidate, aleniglipron, targets obesity, overweight and related conditions; its wholly owned pipeline also includes the experimental oral amylin drugs ACCG-2671 and ACCG-3535.
The aleniglipron late-stage program began in August 2026. Its placebo-controlled studies are enrolling up to 3,600 adults with obesity or overweight and at least one weight-related condition, and up to 1,100 with obesity or overweight and type 2 diabetes. Structure expects results in the second half of 2028 to support global regulatory applications.
Participants start at 2.5 milligrams, with doses increased at four-week intervals toward maintenance doses of 45, 90 or 180 milligrams. The studies will assess long-term effectiveness and safety.
In September 2026, Structure reported 16.2% average weight loss at 72 weeks in the highest-dose group of an earlier trial's extension. Weight loss had not plateaued in the two highest-dose groups. With a 2.5-milligram starting dose, fewer than 5% discontinued treatment because of treatment-emergent adverse events.
“We are developing our commercial readiness plans and see significant opportunity for aleniglipron in both initial weight loss and long-term weight loss maintenance,” Structure Therapeutics CEO Raymond Stevens said in the earnings release.
More Oral Drug Results Ahead
Structure expects fourth-quarter results from a 44-week body-composition study, a 30-week study in adults with type 2 diabetes and obesity or overweight, and a study testing a switch from an approved injectable GLP-1 medicine to daily oral aleniglipron. The switching study evaluates starting doses and weight-loss maintenance over 12 weeks.
ACCG-2671 is undergoing repeat-dose testing over 12 weeks, including daily and weekly regimens and a group adding it to a stable injectable GLP-1 dose. Structure expects results in the first half of 2027. Its September single-dose results in 31 healthy adults without obesity showed an approximately six-day half-life—the time needed for the drug's concentration to fall by half—and no reported serious adverse events.
The company plans to begin early-stage human testing of ACCG-3535 in the fourth quarter of 2026. It also expects to start a study combining oral amylin and GLP-1 medicines in 2027.
Structure is scheduled to present aleniglipron extension and dose-ranging findings Sunday at ObesityWeek 2026 in National Harbor, Maryland. The late-stage program's results remain expected in the second half of 2028.
Sources
- 8-K Filing — Structure Therapeutics Inc. (GPCR) — SEC EDGAR
- Exhibit tm2629207d1_ex99-1.htm — Structure Therapeutics Inc. 8-K exhibit — SEC EDGAR
- Structure Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com
- 8-K filed 2026-09-08 — Structure Therapeutics Inc. (earlier disclosure) — SEC EDGAR